Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral …

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …

Most patients with relapsed/refractory multiple myeloma (RRMM) have been treated with
drug combinations including a proteasome inhibitor (PI) and/or an immunomodulatory drug …

Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that
is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

The outcomes of multiple myeloma (MM) have been improved significantly with the
therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal …

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with
demonstrated activity in hematologic and solid malignancies. Side effects associated with …